Santen Pharmaceutical Co (Santen Pharmaceutical Co) Net Income (Continuing Operations) : $185 Mil (TTM As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Santen Pharmaceutical Co's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was $1 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was $185 Mil.

Santen Pharmaceutical Co Net Income (Continuing Operations) Historical Data

The historical data trend for Santen Pharmaceutical Co's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Net Income (Continuing Operations) Chart

Santen Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Net Income (Continuing Operations)

Get a 7-Day Free Trial

201.68

83.96

229.29

-112.09

178.24

Santen Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income (Continuing Operations)	Get a 7-Day Free Trial															8.27	73.66	59.95	50.74	0.82

Santen Pharmaceutical Co Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $185 Mil.

Santen Pharmaceutical Co (OTCPK:SNPHF) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Santen Pharmaceutical Co Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHF) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

SNPHY:USA 4536:Japan SZD:Germany

Address

Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552

Website

http://www.santen.co.jp

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020